Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis
Authors
Keywords
-
Journal
JOINT BONE SPINE
Volume 89, Issue 5, Pages 105380
Publisher
Elsevier BV
Online
2022-04-28
DOI
10.1016/j.jbspin.2022.105380
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
- (2021) Michael Markus Bonelli et al. ANNALS OF THE RHEUMATIC DISEASES
- SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
- (2021) David Simon et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
- (2021) Robert Spiera et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort
- (2021) Ulf M Geisen et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases
- (2021) Marcia A Friedman et al. ANNALS OF THE RHEUMATIC DISEASES
- Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases
- (2021) Teresa Po-Yu Chiang et al. ANNALS OF THE RHEUMATIC DISEASES
- Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’
- (2021) Jesse Veenstra et al. ANNALS OF THE RHEUMATIC DISEASES
- Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
- (2021) Yolanda Braun-Moscovici et al. ANNALS OF THE RHEUMATIC DISEASES
- SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
- (2021) Daniel Mrak et al. ANNALS OF THE RHEUMATIC DISEASES
- High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases
- (2021) Jake A Ruddy et al. ANNALS OF THE RHEUMATIC DISEASES
- Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
- (2021) Rebecca H Haberman et al. ANNALS OF THE RHEUMATIC DISEASES
- The who international standard for covid-19 serological tests: towards harmonization of anti-spike assays
- (2021) Maria Infantino et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
- (2021) Ugur Sahin et al. NATURE
- Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
- (2021) Ana C. Medeiros-Ribeiro et al. NATURE MEDICINE
- ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
- (2021) Andrea Picchianti-Diamanti et al. Frontiers in Immunology
- The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
- (2021) Satveer K Mahil et al. Lancet Rheumatology
- Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
- (2021) Andrea Rubbert-Roth et al. Lancet Rheumatology
- Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
- (2021) Matthias B Moor et al. Lancet Rheumatology
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
- (2021) Jérôme Avouac et al. Lancet Rheumatology
- Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease
- (2021) Michael D. Kappelman et al. GASTROENTEROLOGY
- SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response
- (2021) Frank Verhoeven et al. JOINT BONE SPINE
- Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study
- (2021) Youn Ho Shin et al. Lancet Rheumatology
- Polymyalgia rheumatica following COVID-19 vaccination: A case-series of ten patients
- (2021) Sébastien Ottaviani et al. JOINT BONE SPINE
- Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: a population-based study in the first two months of COVID-19 outbreak in Italy
- (2020) Luca Quartuccio et al. JOINT BONE SPINE
- Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
- (2020) ANNALS OF THE RHEUMATIC DISEASES
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID‐19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi‐Center Comparative Cohort Study
- (2020) Kristin M. D’Silva et al. Arthritis & Rheumatology
- 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases
- (2019) Victoria Furer et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
- (2015) Kiyoshi Migita et al. ARTHRITIS RESEARCH & THERAPY
- Effect of Methotrexate, Anti-Tumor Necrosis Factor α, and Rituximab on the Immune Response to Influenza and Pneumococcal Vaccines in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2013) Charlotte Hua et al. ARTHRITIS CARE & RESEARCH
- Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
- (2013) Meliha Crnkic Kapetanovic et al. ARTHRITIS RESEARCH & THERAPY
- Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor
- (2011) James J Kobie et al. ARTHRITIS RESEARCH & THERAPY
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started